Feb. 13 at 12:45 AM
$SRTS Why is this decline positive for the company’s future?
Because it reflects a strategic transition away from dependency on a single large buyer and toward diversified recurring models (FDA, direct sales, leases) without compromising financial stability. Cash remains robust, debt-free, and inventory is positioned to support accelerated 2026 placements.
Most important disclosure this time to filter out signal from all the noise - “Delivered 11,411 FDA treatments to 922 patients during 2025, compared with 1,367 treatments delivered to 264 patients during 2024”
